Category: New products
-
Low-Dose Covid-19 Vaccine Generates Strong Immune Response
Ultra-low quantities of an experimental Covid-19 protein vaccine delivered in synthetic cell components are shown in lab animals to generate strong immune responses.
-
Real World Evidence Shown to Emulate Some Clinical Trials
A study of insurance claims records matching the design of randomized clinical trials shows claims data can in some cases resemble clinical trial results to make causal inferences.
-
Biotech Gains $53.7M Infectious Disease Test Award
A maker of diagnostics for infectious diseases is receiving a $53.7 million contract to develop and validate reliable home molecular tests for Covid-19 and flu infections.
-
Trial Shows Plant-Based Drug Helps Reduce Vaping
First results of a clinical trial show a drug derived from plants to aid in smoking cessation helps cut the use of e-cigarettes among non-smokers of burning tobacco.
-
Biotech, Undersea Researchers Partner on Carbon Capture Bacteria
A microbiome biotechnology company and an undersea research group are studying microorganisms that thrive in and consume intense carbon dioxide.
-
Biotech, Dairy Company Collaborate on Plant-Based Cheese
A maker of consumer dairy products and biotechnology food start-up are partnering on plant-based cheeses they say are indistinguishable from today’s dairy cheese.
-
Cancer Cell Therapy Biotech Launches, Raises $10M
A start-up company with a process for harvesting large quantities of cells that infiltrate and kill solid tumors is raising $10 million in seed venture funds.
-
Seaweed Biomaterials Start-Up Gains $5M in Early Funds
A new company creating biomaterials for agriculture and consumer products from large seaweed blooms is adding $5 million in its first venture funding round.
-
Trial Okayed for Glaucoma Treatment Implant
A developer of treatments for eye diseases says it received clearance from FDA to begin a clinical trial of a sustained-release implant therapy for glaucoma.
-
Investor Backing Nanotech Drug Discovery Advances
A life science venture investor is funding further development of a lower-cost molecular-level drug discovery process using nanoscale synthetic DNA strands.